logo and graphic design services.
Looking for eye-catching graphic design services...
From Innovation to Adoption: The Evolution of Continuous Glucose Monitoring Systems
The Continuous Glucose Monitoring (CGM) Market is projected to reach $31.41 billion by 2031, growing at a CAGR of 15.0% from 2024 to 2031. Key drivers of this growth include the increasing prevalence of diabetes, sedentary lifestyles, the advantages of CGM over traditional glucose monitoring methods, and the adoption of CGM by athletes and fitness enthusiasts. Additional factors such as technological advancements, a shift towards personalized healthcare, rising health awareness, and improved accessibility to diabetes care devices in low- and middle-income countries are expected to create significant growth opportunities for CGM market players.Download free sample report here: https://www.meticulousresearch.com/download-sample-report/cp_id=5960?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-08-2024
Market Growth Drivers
Increasing Prevalence of Diabetes
Continuous glucose monitors measure glucose levels and transmit readings to healthcare providers via smartphone apps. Several new CGM products have entered the diabetes management market in recent years. For example, in March 2024, the U.S. FDA approved DexCom, Inc.'s Dexcom Stelo Glucose Biosensor System, an OTC integrated CGM for patients aged 18 and older, suitable for those not on insulin or without severe hypoglycemia.
Risk factors for diabetes include obesity, family history, poor diet, genetic mutations, prediabetes, sedentary lifestyles, and insulin resistance. The World Health Organization (WHO) estimates that approximately 422 million people worldwide have diabetes. CGM helps patients monitor their glucose levels regularly and receive timely alerts for abnormal levels.
Benefits of CGM Over Conventional Glucose Monitoring
Technological advancements have led to the growing use of CGMs, which offer several advantages over traditional devices. These include real-time data monitoring, trend analysis, alerts for high or low glucose levels, improved diabetes management, and reduced reliance on fingerstick testing.
AI integration in CGM devices enhances diabetes management by optimizing treatments and lifestyle choices. For instance, in May 2023, January, Inc. launched an AI-supported app that predicts glucose patterns, integrates with CGM, and provides recommendations on diet and physical activity. This app also offers blood glucose management tips for people without diabetes on special diets.
Browse in depth: https://www.meticulousresearch.com/product/continuous-glucose-monitoring-market-5960?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-08-2024
Market Trends
Shift Toward Smart Devices and Advanced Healthcare with AI
The integration of AI and smart electronic devices in glucose monitoring is a recent trend. Smart CGM devices predict glucose level fluctuations up to 60 minutes in advance and offer insights for better management. For example, Medtronic's Guardian Connect CGM System allows users to track glucose patterns every 5 minutes on mobile devices.
AI in glucose monitoring reduces the need for manual checks by predicting glucose levels and creating personalized plans, making diabetes management more accessible. In March 2024, Roche introduced the AI-powered 14-day Accu-Chek SmartGuide system that predicts glucose fluctuations.
Market Opportunities
Technological Advancements in CGM Devices
Technologically advanced CGMs are gaining popularity due to their enhanced connectivity features, including wireless connectivity, personalized glucose level tracking, integration with insulin pumps, and AI and machine learning integration.
Innovations such as enzyme-based electrochemical sensors in CGM devices provide accurate and reliable information. Many minimally invasive CGMs are enzyme-based. Wireless connectivity with smartphones allows real-time glucose tracking, and integration with insulin pumps enables insulin level adjustments based on glucose levels.
Implantable CGMs are also being introduced. In February 2022, Senseonics Holdings, Inc. received FDA approval for the Eversense® E3, an implantable CGM device that lasts approximately six months.
Download request sample report here: https://www.meticulousresearch.com/request-sample-report/cp_id=5960?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-08-2024
Key Market Findings
By Component: Sensors Segment to Dominate in 2024
The CGM market is segmented into sensors, transmitters, and receivers. In 2024, sensors are expected to hold the largest market share (over 52.4%). This is due to the preference for CGM and the frequent replacement of sensors compared to other components. Disposable sensors are replaced every 7 to 14 days, while implantable sensors can last 150-180 days.
Geographical Analysis
North America to Dominate in 2024
North America is expected to hold the largest market share (over 42.2%) in 2024, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's significant share is due to high accessibility to advanced technologies, the presence of major manufacturers, substantial R&D investments, a robust reimbursement framework, and supportive government initiatives for diabetes awareness. In 2022, U.S. healthcare spending reached $4.5 trillion or $13,493 per person.
However, Asia-Pacific is projected to register the highest CAGR (over 17.40%) during the forecast period, driven by improving healthcare infrastructure, rising disposable incomes, and increased investments by major market players. Economic growth and technological advancements are key factors for market growth in this region.
Quick buy: https://www.meticulousresearch.com/Checkout/64947495?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-08-2024
Key Companies and Recent Developments
Leading Players
Key players in the CGM market include DexCom, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Medtronic PLC, Nemaura Medical Inc., LifeScan, Inc., Senseonics Holdings, Inc., A. Menarini Diagnostics S.r.l, Medtrum Technologies, Inc., and B. Braun SE.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Please login to comment on this Post